

ERYtech Pharma®



The Therapeutic Red Cell Company

International recognition of the ERYtech Pharma R&D platform.

Lyon (France), Philadelphia (USA), April 7, 2010.

ERYtech Pharma is proud to announce that a number of recent advances of the ongoing program will be published in leading scientific journals.

In the next coming weeks, the company will furthermore present the R&D technology platform at several international scientific conventions.

The ERYtech R&D platform is dedicated to in-house products and Business Development agreements.

IMMUNO MODULATION APPLICATIONS

The concept consists in entrapping antigens or peptides into red cells to target in situ the immune cells as macrophages and dendritic cells able to induce an immune response.

Vaccine journal (in press): “In situ targeting of dendritic cells by antigen-loaded red blood cells: A novel approach to cancer immunotherapy” (Banz et al.): [On Elsevier on the following link](#) .

Oral presentation at **TIDES 2010, April 27, 2010, 8:15 am.** Boston, MA, USA: “Red Blood Cells as Unique Biocompatible Carriers for Effective Delivery and Targeting of Therapeutics”; entrapment of oligonucleotides will be also presented [link to event](#).

Poster presentation at **Annual meeting of the International Society of Cell Therapy (ISCT), May 23-26, 2010, Philadelphia, PA, USA:** “Immunotherapy Using Red Blood Cells: Antigen and Adjuvant Delivery System” (Poster Session 1, Monday May 24, 2010 from 5:15 pm – 6:15 pm.) [link to event](#).

Poster at the **7TH International Congress on Autoimmunity, May 5-9, 2010, Ljubljana, Slovenia:** “Induction of antigen-specific immune tolerance by red blood cells: application for auto-immune diseases” (poster). [link to event](#)

RED BLOOD CELLS PROCESSED TO ENHANCE OXYGEN RELEASE

Using the red cells boosted to release more oxygen appears as an efficient therapy to reduce the blood exchanges in patients with sickle cell anemia.

Transfusion journal (in press): “Inositol Hexaphosphate-loaded RBCs prevent *in vitro* sickling” (Bourgeaux *et al.*).

Poster presentation at the **European Haematology Association (EHA) workshop** April 15-18, 2010, Cascais, Portugal: “Inositol hexaphosphate-loaded red blood cells prevent sickling”: [link to event](#).

GRASPA® - L-ASPARAGINASE LOADED RED BLOOD CELLS

GRASPA® is the lead product of ERYtech Pharma in clinical trials.

Oral presentation at the **ISCT annual meeting** “L-Asparaginase Loaded Inside Red Blood Cells As A New Cell Based Medicinal Product” (Oral Abstract Session 7 – Translational Process Development, Wednesday May 26, 2010 from 11:00 am - 12:00 pm).

Poster presentation at the **21st Meeting of the European Association for Cancer Research (EACR)**, June 26-29, 2010, Oslo, Norway: “L-Asparaginase-loaded red blood cells: a promising therapy in solid tumours” [link to event](#).

Oral presentation at the **2010 Leadership National Blood Foundation (NBF)**, April 26-27, 2010, Washington DC, USA for a general speech about GRASPA® and the technology. [link to event](#)

[About ERYtech Pharma](#) ERYtech Pharma is a specialty pharma company developing innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications or sub-populations of patients, particularly in the fields of haematology, cancer and metabolic diseases.

Contact Press:

ERYtech Pharma - 60, Avenue Rockefeller - Bâtiment Adénine - 69008 - LYON - France

ERYtech Pharma - US Office - 3711 Market Street, 19104 Philadelphia PA - USA

[**contact@erytech.com**](mailto:contact@erytech.com)

[**www.erytech.com**](http://www.erytech.com)